300 related articles for article (PubMed ID: 29526442)
1. Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia.
Monogue ML; Ortwine JK; Wei W; Eljaaly K; Bhavan KP
J Infect Public Health; 2018; 11(5):727-731. PubMed ID: 29526442
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.
Schweizer ML; Furuno JP; Harris AD; Johnson JK; Shardell MD; McGregor JC; Thom KA; Cosgrove SE; Sakoulas G; Perencevich EN
BMC Infect Dis; 2011 Oct; 11():279. PubMed ID: 22011388
[TBL] [Abstract][Full Text] [Related]
3. Retrospective Analysis of Adverse Drug Events Between Nafcillin Versus Cefazolin for Treatment of Methicillin-Susceptible
Chan L; Chan-Tompkins NH; Como J; Guarascio AJ
Ann Pharmacother; 2020 Jul; 54(7):662-668. PubMed ID: 31888347
[No Abstract] [Full Text] [Related]
4. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections.
Miller MA; Fish DN; Barber GR; Barron MA; Goolsby TA; Moine P; Mueller SW
J Microbiol Immunol Infect; 2020 Apr; 53(2):321-327. PubMed ID: 30190234
[TBL] [Abstract][Full Text] [Related]
5. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea.
Lee S; Song KH; Jung SI; Park WB; Lee SH; Kim YS; Kwak YG; Kim YK; Kiem SM; Kim HI; Kim ES; Park KH; Kim NJ; Jang HC; Kim HB;
Clin Microbiol Infect; 2018 Feb; 24(2):152-158. PubMed ID: 28694202
[TBL] [Abstract][Full Text] [Related]
6. Does the Beta-Lactam Matter? Nafcillin versus Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections.
Burrelli CC; Broadbent EK; Margulis A; Snyder GM; Gold HS; McCoy C; Mahoney MV; Hirsch EB
Chemotherapy; 2018; 63(6):345-351. PubMed ID: 30965335
[TBL] [Abstract][Full Text] [Related]
7. Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center.
Pollett S; Baxi SM; Rutherford GW; Doernberg SB; Bacchetti P; Chambers HF
Antimicrob Agents Chemother; 2016 Aug; 60(8):4684-9. PubMed ID: 27216053
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Nafcillin and Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia.
Twilla JD; Algrim A; Adams EH; Samarin M; Cummings C; Finch CK
Am J Med Sci; 2020 Jul; 360(1):35-41. PubMed ID: 32376001
[TBL] [Abstract][Full Text] [Related]
9. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?
Lee S; Choe PG; Song KH; Park SW; Kim HB; Kim NJ; Kim EC; Park WB; Oh MD
Antimicrob Agents Chemother; 2011 Nov; 55(11):5122-6. PubMed ID: 21825299
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study.
McDanel JS; Roghmann MC; Perencevich EN; Ohl ME; Goto M; Livorsi DJ; Jones M; Albertson JP; Nair R; O'Shea AMJ; Schweizer ML
Clin Infect Dis; 2017 Jul; 65(1):100-106. PubMed ID: 28379314
[TBL] [Abstract][Full Text] [Related]
11. β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins.
Li J; Echevarria KL; Traugott KA
Pharmacotherapy; 2017 Mar; 37(3):346-360. PubMed ID: 28035690
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study.
Oh DH; Kim JJ; Kim J; Seong H; Lee SJ; Kim YC; Kim EJ; Jung IY; Jeong WY; Jeong SJ; Ku NS; Han SH; Choi JY; Song YG; Kim JM
BMC Infect Dis; 2018 Jan; 18(1):60. PubMed ID: 29378565
[TBL] [Abstract][Full Text] [Related]
13. Methicillin-Susceptible Staphylococcus Aureus Bacteremia: Cefazolin in Prime But Nafcillin Not Ready for an Exit.
Sarria JC
Am J Med Sci; 2020 Jul; 360(1):3-4. PubMed ID: 32439151
[No Abstract] [Full Text] [Related]
14. Clinical implications of cefazolin inoculum effect and β-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia.
Lee S; Kwon KT; Kim HI; Chang HH; Lee JM; Choe PG; Park WB; Kim NJ; Oh MD; Song DY; Kim SW
Microb Drug Resist; 2014 Dec; 20(6):568-74. PubMed ID: 25000230
[TBL] [Abstract][Full Text] [Related]
15. Retrospective Evaluation of the Association of Oxacillin MIC on Acute Treatment Outcomes with Cefazolin and Antistaphylococcal Penicillins in Methicillin-Susceptible Staphylococcus aureus Bacteremia.
Hess KA; Kooda K; Shulha JA; Mara K; Go JR; Fida M; DeSimone DC; Stevens RW
J Clin Microbiol; 2023 Apr; 61(4):e0003923. PubMed ID: 36988505
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting.
Youngster I; Shenoy ES; Hooper DC; Nelson SB
Clin Infect Dis; 2014 Aug; 59(3):369-75. PubMed ID: 24785233
[TBL] [Abstract][Full Text] [Related]
17. The Safety and Economic Impact of Cefazolin versus Nafcillin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections.
Flynt LK; Kenney RM; Zervos MJ; Davis SL
Infect Dis Ther; 2017 Jun; 6(2):225-231. PubMed ID: 28265972
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections.
Rao SN; Rhodes NJ; Lee BJ; Scheetz MH; Hanson AP; Segreti J; Crank CW; Wang SK
Antimicrob Agents Chemother; 2015 Sep; 59(9):5232-8. PubMed ID: 26077253
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia.
Rindone JP; Mellen CK
Br J Clin Pharmacol; 2018 Jun; 84(6):1258-1266. PubMed ID: 29600576
[TBL] [Abstract][Full Text] [Related]
20. Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial.
Cheng MP; Lawandi A; Butler-Laporte G; Paquette K; Lee TC
Trials; 2018 May; 19(1):297. PubMed ID: 29843781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
